Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Next Previous
Search
Trial Profile

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use

Most Recent Events

  • 27 Jan 2018 Results assessing the safety of Adalimumab Dosed Every Week and Every Other Week in patients from this and 12 other studies, published in the American Journal of Clinical Dermatology
  • 07 Nov 2015 Pooled analysis, efficacy and prior treatment analysis, results published in the American Journal of Clinical Dermatology
  • 24 Mar 2015 Pooled analysis results presented at the 73rd Annual Meeting of the American Academy of Dermatology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top